Kawasaki, Ryo http://orcid.org/0000-0002-7492-6303
,
Kitano, Shigehiko
Sato, Yukihiro
Yamashita, Hidetoshi
Nishimura, Rimei
Tajima, Naoko
Funding for this research was provided by:
Ministry of Health, Labour and Welfare
Manpei Suzuki Diabetes Foundation
Japan Diabetes Society
Article History
Received: 6 March 2018
Accepted: 21 April 2018
First Online: 26 April 2018
Compliance with ethical standards
:
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent or substitute for it was obtained from all patients for being included in the study. The study protocol was reviewed and approved by the Research Ethics Review Board of the Japan Diabetes Society (approved on July 2, 2013; study title “Japan Diabetes Complication and its Prevention Prospective study (JDCP study); approval number: not applicable).
: Research funding: Pfizer (RK), Rohto (RK), Novartis (RK, KS, HY, RN), Bayer (RK, KS), Santen (KS, HY), Senju (RK, KS), Alcon Japan (KS, HY), Funayama Hospital (HY), Trust Medical (HY), Sanofi (RN), Japan Medtronic (RN), Japan Boehringer-Ingelheim (RN, TN), Takeda (RN, TN), Kissei (RN, TN), Eli Lily (RN), Novo Nordisk (RN, TN), Astellas (RN, TN), Abbott Japan (TN), and MSD (TN). Endowed department: Topcon (RK).